Nifty
:
11642.40
Sensex
:
39614.07
-28.40 (-0.24%)
-135.78 (-0.34%)
Nifty
Sensex
:
:
11642.40
39614.07
-28.40 (-0.24%)
-135.78 (-0.34%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
63/99

BSE: 532531 | NSE: STAR

NSE BSE
690.30
30-Oct-2020
  • Open
  • High
  • Low
  • Previous Close
  •  688.00
  •  703.00
  •  658.30
  •  674.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1352447
  •  9242.95
  •  764.40
  •  268.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,181.26
  • 83.00
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,905.90
  • 2.03%
  • 2.30

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 29.69%
  • 0.00%
  • 15.14%
  • FII
  • DII
  • Others
  • 26.96%
  • 15.14%
  • 13.07%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 0.82
  • -3.76

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.04
  • 16.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 4.87
  • -40.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.35
  • 23.25
  • 10.38

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.00
  • 2.54
  • 1.70

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.57
  • 14.68
  • 12.55

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
793.56
715.09
10.97%
781.80
685.80
14.00%
618.64
616.18
0.40%
732.44
569.89
28.52%
Expenses
636.35
568.50
11.93%
630.79
564.88
11.67%
553.60
523.83
5.68%
551.60
508.83
8.41%
EBITDA
157.21
146.59
7.24%
151.01
120.92
24.88%
65.04
92.35
-29.57%
180.84
61.06
196.17%
EBIDTM
19.81%
20.50%
19.32%
17.63%
14.01%
14.99%
24.69%
10.71%
Other Income
17.75
14.07
26.15%
16.20
10.25
58.05%
17.65
16.99
3.88%
13.65
9.65
41.45%
Interest
36.87
40.42
-8.78%
36.91
35.34
4.44%
40.33
23.36
72.65%
39.63
21.90
80.96%
Depreciation
52.79
42.00
25.69%
49.13
42.89
14.55%
45.34
29.65
52.92%
43.47
27.87
55.97%
PBT
98.44
161.68
-39.11%
126.08
46.29
172.37%
-173.08
72.27
-
127.02
34.55
267.64%
Tax
6.10
7.38
-17.34%
3.28
3.12
5.13%
-10.47
-7.55
-
11.30
-0.23
-
PAT
92.34
154.30
-40.16%
122.80
43.17
184.46%
-162.61
79.82
-
115.72
34.78
232.72%
PATM
11.64%
21.58%
15.71%
6.29%
7.11%
12.95%
15.80%
6.10%
EPS
10.31
17.22
-40.13%
13.71
4.82
184.44%
-18.15
8.91
-
12.92
3.88
232.99%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Net Sales
2,926.44
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
Net Sales Growth
13.12%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
 
Cost Of Goods Sold
5,515.89
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
Gross Profit
-2,589.45
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
GP Margin
-88.48%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
Total Expenditure
2,372.34
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
Power & Fuel Cost
-
64.49
54.39
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
% Of Sales
-
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
Employee Cost
-
442.56
329.44
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
% Of Sales
-
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
Manufacturing Exp.
-
210.79
150.98
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
% Of Sales
-
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
General & Admin Exp.
-
191.89
150.10
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
% Of Sales
-
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
Selling & Distn. Exp.
-
137.07
111.22
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
% Of Sales
-
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
Miscellaneous Exp.
-
301.61
930.33
725.25
1,103.88
96.95
29.44
58.33
93.69
50.21
88.02
% Of Sales
-
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
EBITDA
554.10
510.22
296.68
235.71
516.92
380.57
228.85
223.42
100.58
490.68
326.62
EBITDA Margin
18.93%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
Other Income
65.25
66.70
322.90
920.64
398.08
102.37
38.57
60.23
34.20
31.67
69.70
Interest
153.74
155.72
79.29
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
Depreciation
190.73
187.79
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
PBT
178.46
233.42
368.44
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
Tax
10.21
17.91
14.49
21.41
51.19
42.45
147.60
40.86
11.15
38.68
45.19
Tax Rate
5.72%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
PAT
168.25
143.62
370.31
681.31
399.38
113.21
1.57
50.89
712.39
224.48
122.45
PAT before Minority Interest
175.49
137.82
375.57
701.18
445.58
99.68
0.98
50.89
713.44
234.01
141.18
Minority Interest
7.24
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
PAT Margin
5.75%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
PAT Growth
-46.09%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
 
EPS
18.78
16.03
41.33
76.04
44.57
12.64
0.18
5.68
79.51
25.05
13.67

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Shareholder's Funds
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
Share Capital
89.56
89.55
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
Total Reserves
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
Non-Current Liabilities
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
Secured Loans
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
Unsecured Loans
2.12
0.06
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
Long Term Provisions
63.95
52.24
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
Current Liabilities
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
Trade Payables
797.75
888.99
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
Other Current Liabilities
354.49
248.12
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
Short Term Borrowings
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
Short Term Provisions
163.84
186.11
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
Total Liabilities
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
Net Block
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
Gross Block
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
Accumulated Depreciation
508.53
478.92
326.03
277.09
146.75
379.19
352.80
497.57
457.19
298.44
Non Current Assets
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
Capital Work in Progress
412.95
453.03
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
Non Current Investment
503.24
494.34
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
Long Term Loans & Adv.
208.24
223.69
197.22
222.56
201.83
96.72
90.40
118.75
229.99
0.00
Other Non Current Assets
430.77
16.86
30.72
15.62
22.62
1.91
1.45
6.96
8.67
0.00
Current Assets
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
Current Investments
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
Inventories
782.54
874.16
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
Sundry Debtors
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
Cash & Bank
237.10
516.65
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
Other Current Assets
301.81
136.87
138.84
209.70
343.44
123.64
136.26
319.58
347.17
925.17
Short Term Loans & Adv.
218.24
249.11
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
Net Current Assets
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
Total Assets
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Cash From Operating Activity
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
PBT
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
Adjustment
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
Changes in Working Capital
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
Cash after chg. in Working capital
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
Net Fixed Assets
-115.07
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
Net Investments
-17.17
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
Others
1,438.40
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
Cash from Financing Activity
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
Net Cash Inflow / Outflow
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
Opening Cash & Equivalents
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
Closing Cash & Equivalent
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Book Value (Rs.)
281.55
294.94
274.26
306.41
296.83
191.91
168.99
343.78
233.49
220.07
ROA
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
ROE
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
ROCE
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
Fixed Asset Turnover
1.50
1.17
1.04
1.27
1.47
1.21
0.61
0.27
0.82
0.72
Receivable days
70.88
79.95
102.49
96.77
90.73
114.71
114.80
193.43
65.68
86.42
Inventory Days
61.20
61.00
70.11
64.20
52.34
58.37
83.78
174.61
56.40
58.62
Payable days
138.58
146.59
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
Cash Conversion Cycle
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
114.76
29.50
25.22
Total Debt/Equity
0.78
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
Interest Cover
2.00
5.92
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011
FY 2010

News Update:


  • Strides Pharma’s arm gets USFDA’s nod for Ethacrynic Acid Tablets
    20th Oct 2020, 12:00 PM

    The company has 126 cumulative ANDA filings with USFDA of which 92 ANDAs have been approved and 34 are pending approval

    Read More
  • Strides Pharma’s arm gets USFDA nod for Butalbital, Acetaminophen, Caffeine Tablets
    22nd Sep 2020, 12:58 PM

    The product will be marketed by Strides Pharma Inc. in the US market

    Read More
  • Strides unveils SteriScience as its dedicated arm for sterile injectables
    14th Sep 2020, 14:37 PM

    The transaction with Brooks is subject to approval from the shareholders of Brooks

    Read More
  • Strides Pharma’s arm gets USFDA’s nod for Prednisone Tablets
    3rd Sep 2020, 16:00 PM

    The US market for Prednisone Tablets USP, 1 mg is approximately $12 million

    Read More
  • Strides Pharma Science’s arm gets USFDA’s approval for Ursodiol Tablets
    21st Aug 2020, 12:40 PM

    The product will be manufactured at the company’s flagship facility at Bengaluru

    Read More
  • UK MHRA completes inspection at Strides Pharma Science’s Puducherry facility
    20th Aug 2020, 11:28 AM

    The company has now received the renewed GMP certificate thereby confirming the successful closure of the inspection

    Read More
  • Strides Pharma Scien - Quarterly Results
    5th Aug 2020, 13:41 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.